Melanoma Clinical Trial

Prospective Matched Case-Control Study With AU-011 or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Summary

This is a prospective multicenter, matched case-control study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with AU-011 and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.

View Full Description

Full Description

Up to approximately 45 patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the Investigator are planned to be enrolled.

View Eligibility Criteria

Eligibility Criteria

Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.

Study is for people with:

Melanoma

Estimated Enrollment:

45

Study ID:

NCT05266430

Recruitment Status:

Recruiting

Sponsor:

Aura Biosciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Associated Retinal Consultants, P.C.
Royal Oak Michigan, 48073, United States More Info
Kendra Mellert
Contact
248-288-9132
[email protected]
Elise Kowalski
Contact
248-288-9132
[email protected]
Antonio Capone, Jr., MD
Principal Investigator
Oregon Health & Science University Casey Eye Institute
Portland Oregon, 97239, United States More Info
Ann Lundquist
Contact
503-494-6364
[email protected]
Alison Skalet, MD
Principal Investigator
Retina Consultants of Carolina, PA
Greenville South Carolina, 29605, United States More Info
Lauren Frazier
Contact
864-233-5722
[email protected]
Chris Bergstrom, MD
Principal Investigator
St. Thomas Health/Tennessee Retina, P.C.
Nashville Tennessee, 37203, United States More Info
Lisa Walden
Contact
615-345-8912
[email protected]
Nicholas Jones
Contact
16294014009
[email protected]
David Reichstein, MD
Principal Investigator
Retina Consultants of Texas
Bellaire Texas, 77401, United States More Info
Alex Brown
Contact
713-524-3434
[email protected]
Kourtney Storey
Contact
713-524-3434
[email protected]
Amy Schefler, MD
Principal Investigator
Texas Retina Associates
Dallas Texas, 75231, United States More Info
Marisa Kubacki
Contact
214-692-6941
[email protected]
Sally Arceneaux
Contact
214-692-6885
[email protected]
Timothy Fuller, MD
Principal Investigator
University of Wisconsin Dept of Ophthalmology & Visual Sciences
Madison Wisconsin, 53705, United States More Info
Bonnie Verges
Contact
608-265-4659
[email protected]
Kris Dietzman
Contact
608-265-4659
[email protected]
Michael Altaweel, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

45

Study ID:

NCT05266430

Recruitment Status:

Recruiting

Sponsor:


Aura Biosciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.